CCL2 and breast cancer: Silencing CCL2 expression by TAT cell-penetrating peptides noncovalently cross-linked to siRNAs (Ca-TAT/siRNA) significantly reduced CCL2 expression in PyMT mammary tumors and decreased cell proliferation and survival.